536 results on '"Reed, Eddie"'
Search Results
102. Abstract 605: Olive polyphenol, hydroxytyrosol, exerts anti-tumor effects in prostate cancer cells by targeting Akt, STAT3 and AR signaling
103. Abstract 5613: A specific isoform of Gli1 binds the Gli-binding site of the c-jun and c-fos promoters
104. Abstract 834: Inhibition of Gli1 results in altered c-jun activation, inhibition of cisplatin-induced up-regulation of ERCC1, XPD, and XRCC1, and inhibition of platinum-DNA adduct repair
105. Double Prophylaxis for Deep Venous Thrombosis in Patients With Gynecologic Oncology Who Are Undergoing Laparotomy
106. Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications
107. Abstract 2156: c-Myb promotes growth, invasion and androgen-independence of prostate cancer cells
108. Abstract 3406: Understanding molecular pathway differences between ovarian cancer stem cells (OCSC) and non-ovarian cancer stem cells (non-OCSC) leads to the Hedgehog pathway as a common thread
109. Abstract 249: Inhibition of protein phosphatase 2A supports androgen-independent growth of prostate cancer cells
110. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity
111. Carboplatin and Renal Dysfunction
112. DNA Damage and Repair in Translational Oncology: An Overview
113. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary
114. Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age
115. Older women as the focus for research and treatment of ovarian cancer: An overview for the national institute on aging, national cancer institute, and American cancer society multidisciplinary working conference
116. A Polymorphic Variant of AFAP-110 Enhances cSrc Activity
117. Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer
118. Abstract LB-281: Inhibition of Hedgehog results in altered regulation of c-jun and of ERCC1 in cisplatin-resistant A2780-CP70 human ovarian cancer cells
119. Abstract CN4-3: Factors that influence the regulation of ERCC1 in drug-resistant cells
120. Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1
121. In vitro combination characterization of the new anticancer plant drug β-elemene with taxanes against human lung carcinoma
122. A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy
123. BRCA1 Contributes to Cell Cycle Arrest and Chemoresistance in Response to the Anticancer Agent Irofulven
124. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven
125. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells
126. Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo
127. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer
128. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa
129. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum β-lactamase-producing Escherichia coli bacteremia
130. ERCC1 and Clinical Resistance to Platinum-Based Therapy
131. Molecular mechanism of antitumor activity of taxanes in lung cancer (Review)
132. Overexpression of the N-terminal end of the p55γ regulatory subunit of phosphatidylinositol 3-kinase blocks cell cycle progression in gastric carcinoma cells
133. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis
134. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells
135. Apigenin inhibits VEGF and HIF‐1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways
136. Characterization of the mechanisms of electrochemotherapy in an in vitro model for human cervical cancer
137. Guest Commentary: Reflections on the Practical Realities of Cancer Control
138. Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancer
139. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)
140. SU5416 inhibited VEGF and HIF-1α expression through the PI3K/AKT/p70S6K1 signaling pathway
141. Apoptosis in prostate cancer: Progressive and therapeutic implications (Review)
142. ATM-dependent CHK2 Activation Induced by Anticancer Agent, Irofulven
143. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells
144. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma
145. 9-β-d-Arabinofuranosyl-2-fluoroadenine Inhibits Expression of Vascular Endothelial Growth Factor through Hypoxia-Inducible Factor-1 in Human Ovarian Cancer Cells
146. Detection of Cyclin B1 Expression in G1-Phase Cancer Cell Lines and Cancer Tissues by Postsorting Western Blot Analysis
147. Neuro-optic cell apoptosis and microangiopathy in KKAY mouse retina
148. Effects of Kupffer cell inhibition on liver function and hepatocellular activity in mice
149. Effects of thalidomide on the expression of angiogenesis growth factors in human A549 lung adenocarcinoma cells
150. Randomized Double Blind, Placebo Controlled Trial of Neuroprotective Effects of Epoetin alfa (Procrit)in Patients Receiving Adjuvant Chemotherapy for Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.